Companion Diagnostics Market Size to Exceed USD 22.48 Bn by 2033

The Companion Diagnostics Market, estimated at USD 9.86 Bn in 2026, is expected to exhibit a CAGR of 12.5 % and reach USD 22.48 Bn by 2033.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

The demand for personalized medicine has been steadily increasing over the past decade. With advancements in fields like genomics and proteomics, medical professionals have a more comprehensive understanding of the molecular characteristics of diseases. This is driving the growth of targeted therapies that are developed for specific patient populations, which are based on biomarkers. Companion diagnostics help identify whether a patient is likely to respond well or poorly, to a particular targeted therapy that is based on the presence or absence of certain biomarkers.

Global Companion Diagnostics Market: Key Developments

Increasing inorganic growth strategies such as collaboration by key market players are expected to aid in the growth of the global companion diagnostics market. For instance, in August 2022, BD a medical device company, collaborated with Labcorp, a life science company, to develop, manufacture, market, and commercialize flow cytometry that is based on companion diagnostics (CDx) which is intended to match patients with life-changing treatments for cancer and other diseases.

Browse 35 Market Data Tables and 35 Figures spread through 160 Pages and in-depth TOC on “Global Companion Diagnostics Market”- Forecast to 2033, Global Companion Diagnostics Market, By Technology Type (Real Time-Polymerase Chain Reactions (PCR), Gene Sequencing, Fluorescence in situ Hybridization, and Others), By Application (Oncology,  Cardiovascular Diseases,  Infectious Diseases,  Neurological Diseases and Others), By End User ( Hospitals,  Research Laboratories, Biopharmaceutical companies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109

Recent Development

• In May 2026, Indica Labs, biotechnology company unveiled an AI-powered companion diagnostics offering ahead of ASCO 2026, expanding its CDx capabilities for precision medicine. The portfolio uses HALO digital pathology platforms, advanced AI models, and quantitative biomarker analysis to support tissue classification, phenotypic profiling, ADC analysis, multiplexed IHC, and continuous scoring. The company also formed a Precision Medicine team to help pharma partners advance biomarker discovery, validation, and global regulatory submission pathways. (Source: Indica Labs)
• In January 2026, Cardio Diagnostics, Aimil Ltd., and Dr. Lal PathLabs partnered to launch the PrecisionCHD test in India. The AI-driven blood test combines epigenetics and genetics to detect coronary heart disease at a molecular level, including non-obstructive CHD. The collaboration marks Cardio Diagnostics’ first expansion outside the U.S. and supports improved early detection, personalized treatment, and heart disease management across Dr. Lal PathLabs’ clinical network.
• In July 2026, Biocartis NV, molecular diagnostics company and Discovery Life Sciences, a global specialty lab services provider and biospecimen provider announced a strategic collaboration to deliver end-to-end precision oncology diagnostics for pharmaceutical and biotech companies worldwide. The partnership combines Discovery’s clinical laboratory network and biorepository with Biocartis’ automated Idylla PCR platform, generating molecular biomarker results in about three hours. It supports companion diagnostic development, clinical trial assays, KRAS testing, biomarker discovery, and harmonized U.S.-EU oncology trial workflows for faster patient enrollment globally.

Key Takeaways of the Global Companion Diagnostics Market

• Global companion diagnostics market is expected to exhibit a CAGR of 12.5% during the forecast period due to the increasing inorganic gtowth strategies such as partnership by market players. For instance, on January 05, 2023, QIAGEN a molecular diagnostics manufacturer, enter into strategic partnership with Helix a genomics company, to launch next-generation sequencing companion diagnostics for hereditary diseases. These diagnostics helps to guide in clinical decision-making by identifying patients who are most likely to benefit or be at increased risk from a particular therapeutic product.
• Among technology type, the real time-polymerase chain reactions (PCR) segment is estimated to hold a dominant position in the global companion diagnostics market over the forecast period. For instance, in June 2022, Hoffmann-La Roche Ltd. a pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval of the cobas EZH2 Mutation Test as a companion diagnostic for TAZVERIK (tazemetostat) treatment. This molecular test detects abnormalities in the Enhancer of Zeste Homolog 2 (EZH2) gene, in patients with follicular lymphoma (FL), a type of non-Hodgkin lymphoma patients who may be eligible for treatment with TAZVERIK.
• Among region, North America is expected to be the dominant region in the global companion diagnostics market, due to several factors supporting the widespread adoption of real time-PCR technologies across clinical laboratories and diagnostic centers in the region, which is expected to drive segment growth over the forecast period. Real time-PCR assays offer high throughput, sensitivity, and accuracy that is needed for companion diagnostic applications. They have become the gold standard for detecting gene variations responsible for medication responses. For example, F. Hoffmann-La Roche Ltd a pharmaceutical company’s cobas system that is used to detect EGFR mutations in lung cancer patients aiding targeted therapy decisions, processes over 1000 samples daily across major hospitals in the U.S. and Canada using real time-PCR. Similarly, Thermo Fisher Scientific Inc. a biotechnology company’s QuantStudio real time-PCR instruments are used in over 80% of clinical molecular diagnostic labs as per the College of American Pathologists, due to their ability to quickly analyze numerous patient samples on a single run.
• Major players operating in the global companion diagnostics market include F. Hoffmann-La Roche AG, Agilent Technologies, Inc., QIAGEN N.V, Abbott Laboratories, Inc., Almac Group, Danaher Corporation, Illumina, Inc., bioMérieux SA, Myriad Genetics, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Abnova Corporation, Guardant Health, Inc., Icon Plc., and Biogenex Laboratories, Inc.